Targovax ASA logo

TRVXo - Targovax ASA News Story

NOK6.38 -0.0  -0.6%

Last Trade - 11:19am

Sector
Healthcare
Size
Micro Cap
Market Cap £41.3m
Enterprise Value £35.7m
Revenue £217k
Position in Universe 1012th / 1782

BRIEF-Targovax Announces Collaborative Agreement With Merck & Co

Tue 23rd June, 2020 6:10am
June 23 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN
COMBINATION WITH KEYTRUDA ®  IN MESOTHELIOMA
    * COLLABORATIVE AGREEMENT WITH MERCK & CO., INC.,
KENILWORTH, NJ,
USA
    * AIM IS TO START ENROLLING PATIENTS INTO TRIAL WITHIN
TWELVE
MONTHS
    * MULTIPLE CENTERS IN BOTH USA AND EU WILL BE PARTICIPATING
    * TO EVALUATE COMBINATION OF ONCOS-102, KEYTRUDA MSD'S
ANTI-PD-1
THERAPY, AND STANDARD OF CARE CHEMOTHERAPY IN MALIGNANT PLEURAL
MESOTHELIOMA
    * TRIAL WILL BE A RANDOMIZED PHASE II OF UP TO 100 PATIENTS
COMPARING THIS INVESTIGATIONAL TRIPLE COMBINATION AGAINST
KEYTRUDA AND SOC

Source text for Eikon:  ID:nWkr47LFMn 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.